Novel CNS ion channel

The "Novel CNS ion channel" is a placeholder designation for an undisclosed therapeutic target within the central nervous system, currently the focus of high-profile drug discovery collaborations involving the biotechnology company Saniona. Most notably, Saniona is partnering with Boehringer Ingelheim to develop first-in-class modulators for this target to treat cognitive impairment associated with schizophrenia (CIAS), a condition with significant unmet medical need (Saniona Press Release, 2024; BioStock, 2024). A separate collaboration with AstronauTx targets a similarly undisclosed novel ion channel for the treatment of Alzheimer's disease and other neurodegenerative conditions (Saniona Press Release, 2023). These programs leverage advanced ion channel screening platforms to identify selective, subtype-specific modulators that can restore normal neuronal signaling. As of late 2024, the schizophrenia program has advanced to the lead optimization stage, indicating that selective small-molecule leads have been identified and are being refined for clinical potential (MFN, 2024; BioWorld, 2023). Because the specific protein identity has not been publicly revealed, the target is currently referred to by this descriptive title in industry communications.

Other names

Undisclosed CNS ion channel targetSaniona-Boehringer Ingelheim schizophrenia targetSaniona-AstronauTx Alzheimer's target

Ion channel modulation